Search

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

Read more

Highlights of Past EHA - Cairo 2017

Dates: September 14 - 15, 2017
Location: Cairo, Egypt
Chairs: 
Prof Azza Kamel, Secretary General, Egyptian Society of Hematology and Research (ESHR)
Prof Amal El-Beshlawy, Vice President, Egyptian Society of Hematology and Research (ESHR)
Prof John Gribben, President elect, European Hematology Association (EHA)
Prof Mohamad Qari, President, Pan…

Read more

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Read more

EHA Statement of Solidarity with Ukraine

The European Hematology Association (EHA) is deeply concerned about the situation in Ukraine, the plight of the civilian population, and the damage to healthcare infrastructures.

Read more

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

Substances of Human Origin (SoHO) legislation

EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.

Read more